These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 27487775)
1. Characteristics and outcomes of women initiating ART during pregnancy versus breastfeeding in Option B+ in Malawi. Landes M; Sodhi S; Matengeni A; Meaney C; van Lettow M; Chan AK; van Oosterhout JJ BMC Public Health; 2016 Aug; 15():713. PubMed ID: 27487775 [TBL] [Abstract][Full Text] [Related]
2. HIV-positive pregnant and postpartum women's perspectives about Option B+ in Malawi: a qualitative study. Katirayi L; Namadingo H; Phiri M; Bobrow EA; Ahimbisibwe A; Berhan AY; Buono N; Moland KM; Tylleskär T J Int AIDS Soc; 2016; 19(1):20919. PubMed ID: 27312984 [TBL] [Abstract][Full Text] [Related]
3. Same day HIV diagnosis and antiretroviral therapy initiation affects retention in Option B+ prevention of mother-to-child transmission services at antenatal care in Zomba District, Malawi. Chan AK; Kanike E; Bedell R; Mayuni I; Manyera R; Mlotha W; Harries AD; van Oosterhout JJ; van Lettow M J Int AIDS Soc; 2016; 19(1):20672. PubMed ID: 26976377 [TBL] [Abstract][Full Text] [Related]
4. Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study. Haas AD; Tenthani L; Msukwa MT; Tal K; Jahn A; Gadabu OJ; Spoerri A; Chimbwandira F; van Oosterhout JJ; Keiser O Lancet HIV; 2016 Apr; 3(4):e175-82. PubMed ID: 27036993 [TBL] [Abstract][Full Text] [Related]
5. Towards elimination of mother-to-child transmission of HIV: performance of different models of care for initiating lifelong antiretroviral therapy for pregnant women in Malawi (Option B+). van Lettow M; Bedell R; Mayuni I; Mateyu G; Landes M; Chan AK; van Schoor V; Beyene T; Harries AD; Chu S; Mganga A; van Oosterhout JJ J Int AIDS Soc; 2014; 17(1):18994. PubMed ID: 25079437 [TBL] [Abstract][Full Text] [Related]
6. Adherence to Antiretroviral Therapy During and After Pregnancy: Cohort Study on Women Receiving Care in Malawi's Option B+ Program. Haas AD; Msukwa MT; Egger M; Tenthani L; Tweya H; Jahn A; Gadabu OJ; Tal K; Salazar-Vizcaya L; Estill J; Spoerri A; Phiri N; Chimbwandira F; van Oosterhout JJ; Keiser O Clin Infect Dis; 2016 Nov; 63(9):1227-1235. PubMed ID: 27461920 [TBL] [Abstract][Full Text] [Related]
7. Retention in care and reasons for discontinuation of lifelong antiretroviral therapy in a cohort of Cameroonian pregnant and breastfeeding HIV-positive women initiating 'Option B+' in the South West Region. Atanga PN; Ndetan HT; Achidi EA; Meriki HD; Hoelscher M; Kroidl A Trop Med Int Health; 2017 Feb; 22(2):161-170. PubMed ID: 27865052 [TBL] [Abstract][Full Text] [Related]
8. HIV transmission and retention in care among HIV-exposed children enrolled in Malawi's prevention of mother-to-child transmission programme. Haas AD; van Oosterhout JJ; Tenthani L; Jahn A; Zwahlen M; Msukwa MT; Davies MA; Tal K; Phiri N; Spoerri A; Chimbwandira F; Egger M; Keiser O J Int AIDS Soc; 2017 Sep; 20(1):21947. PubMed ID: 28884524 [TBL] [Abstract][Full Text] [Related]
9. Acceptability of lifelong treatment among HIV-positive pregnant and breastfeeding women (Option B+) in selected health facilities in Zimbabwe: a qualitative study. Chadambuka A; Katirayi L; Muchedzi A; Tumbare E; Musarandega R; Mahomva AI; Woelk G BMC Public Health; 2017 Jul; 18(1):57. PubMed ID: 28743251 [TBL] [Abstract][Full Text] [Related]
10. Timing of HIV testing among pregnant and breastfeeding women and risk of mother-to-child HIV transmission in Malawi: a sampling-based cohort study. Chagomerana MB; Edwards JK; Zalla LC; Carbone NB; Banda GT; Mofolo IA; Hosseinipour MC; Herce ME J Int AIDS Soc; 2021 Mar; 24(3):e25687. PubMed ID: 33749155 [TBL] [Abstract][Full Text] [Related]
11. Understanding factors, outcomes and reasons for loss to follow-up among women in Option B+ PMTCT programme in Lilongwe, Malawi. Tweya H; Gugsa S; Hosseinipour M; Speight C; Ng'ambi W; Bokosi M; Chikonda J; Chauma A; Khomani P; Phoso M; Mtande T; Phiri S Trop Med Int Health; 2014 Nov; 19(11):1360-6. PubMed ID: 25087778 [TBL] [Abstract][Full Text] [Related]
12. Patterns of HIV Care Clinic Attendance and Adherence to Antiretroviral Therapy Among Pregnant and Breastfeeding Women Living With HIV in the Context of Option B+ in Zimbabwe. Erlwanger AS; Joseph J; Gotora T; Muzunze B; Orne-Gliemann J; Mukungunugwa S; Farley T; Mangwiro AZ J Acquir Immune Defic Syndr; 2017 Jun; 75 Suppl 2():S198-S206. PubMed ID: 28498190 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz. Harrington BJ; DiPrete BL; Jumbe AN; Ngongondo M; Limarzi L; Wallie SD; Chagomerana MB; Hosseinipour MC; Trop Med Int Health; 2019 Oct; 24(10):1221-1228. PubMed ID: 31381233 [TBL] [Abstract][Full Text] [Related]
14. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Sturt AS; Dokubo EK; Sint TT Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370 [TBL] [Abstract][Full Text] [Related]
15. Lessons learned from the PMTCT program in Swaziland: challenges with accepting lifelong ART for pregnant and lactating women - a qualitative study. Katirayi L; Chouraya C; Kudiabor K; Mahdi MA; Kieffer MP; Moland KM; Tylleskar T BMC Public Health; 2016 Oct; 16(1):1119. PubMed ID: 27776495 [TBL] [Abstract][Full Text] [Related]
16. Baseline characteristics of study sites and women enrolled in a three-arm cluster randomized controlled trial: PMTCT uptake and retention (pure) Malawi. van Lettow M; Tweya H; Rosenberg NE; Trapence C; Kayoyo V; Kasende F; Kaunda B; Hosseinipour MC; Eliya M; Cataldo F; Gugsa S; Phiri S; Reprod Health; 2017 Jul; 14(1):82. PubMed ID: 28693525 [TBL] [Abstract][Full Text] [Related]
17. Supporting Option B+ scale up and strengthening the prevention of mother-to-child transmission cascade in central Malawi: results from a serial cross-sectional study. Herce ME; Mtande T; Chimbwandira F; Mofolo I; Chingondole CK; Rosenberg NE; Lancaster KE; Kamanga E; Chinkonde J; Kumwenda W; Tegha G; Hosseinipour MC; Hoffman IF; Martinson FE; Stein E; van der Horst CM BMC Infect Dis; 2015 Aug; 15():328. PubMed ID: 26265222 [TBL] [Abstract][Full Text] [Related]
18. Viral Suppression and HIV Drug Resistance at 6 Months Among Women in Malawi's Option B+ Program: Results From the PURE Malawi Study. Hosseinipour M; Nelson JAE; Trapence C; Rutstein SE; Kasende F; Kayoyo V; Kaunda-Khangamwa B; Compliment K; Stanley C; Cataldo F; van Lettow M; Rosenberg NE; Tweya H; Gugsa S; Sampathkumar V; Schouten E; Eliya M; Chimbwandira F; Chiwaula L; Kapito-Tembo A; Phiri S; J Acquir Immune Defic Syndr; 2017 Jun; 75 Suppl 2(Suppl 2):S149-S155. PubMed ID: 28498184 [TBL] [Abstract][Full Text] [Related]
19. Implementation of Option B and a fixed-dose combination antiretroviral regimen for prevention of mother-to-child transmission of HIV in South Africa: A model of uptake and adherence to care. Maskew M; Jamieson L; Mohomi G; Long L; Mongwenyana C; Nyoni C; Mokaba D; Fox MP; Sanne I; Rosen S PLoS One; 2018; 13(8):e0201955. PubMed ID: 30161147 [TBL] [Abstract][Full Text] [Related]
20. Assessing Option B+ retention and infant follow-up in Lilongwe, Malawi. Hauser BM; Miller WC; Tweya H; Speight C; Mtande T; Phiri S; Ball LM; Hosseinipour MC; Hoffman IF; Rosenberg NE Int J STD AIDS; 2018 Feb; 29(2):185-194. PubMed ID: 28750577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]